| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
|
Purity: ≥98%
Norfloxacin (AM-715; MK 0366; MK0366; AM715; MK-366; AM 715; MK366; MK 366; Noroxin; Chibroxin) is a broad-spectrum and synthetic chemotherapeuticantibiotic approved for the treatment of UTIs-urinary tract infections. It functions by blocking DNA gyrase and is effective against both Gram-positive and Gram-negative bacteria. Urinary tract infections, both simple and complex, are treated with norfloxacin. It is a first-generation synthetic fluoroquinolone that is authorized for the treatment of prostatitis, uTIs, and STDs, though the latter are no longer treated with it because of bacterial resistance.
| Targets |
Quinolone
|
|---|---|
| ln Vitro |
Norfloxacin (MK-0366) is a synthetic antibacterial chemotherapeutic agent that is occasionally used to treat both simple and complex urinary tract infections. Broad-spectrum antibiotic norfloxacin (MK-0366) is effective against both Gram-positive and Gram-negative bacteria. It stops cell division by blocking enzymes that are required to separate bacterial DNA, such as DNA gyrase, a type II topoisomerase, and topoisomerase IV. Currently, the adult population has three approved uses—one of which is restricted—and the other is ineffective because of bacterial resistance.
|
| References |
|
| Molecular Formula |
C16H18FN3O3
|
|---|---|
| Molecular Weight |
319.3308
|
| Exact Mass |
319.13
|
| Elemental Analysis |
C, 60.18; H, 5.68; F, 5.95; N, 13.16; O, 15.03
|
| CAS # |
70458-96-7
|
| Related CAS # |
68077-27-0；118803-81-9
|
| Appearance |
Solid powder
|
| SMILES |
CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O
|
| InChi Key |
OGJPXUAPXNRGGI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
|
| Chemical Name |
1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
|
| Synonyms |
MK-0366; Norfloxacin; AM-715; MK 0366; MK0366; AM715; MK-366; AM 715; MK366; MK 366; Noroxin; Chibroxin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 3~5 mg/mL (9.4~15.7 mM)
Water : <1 mg/mL Ethanol : <1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (1.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1316 mL | 15.6578 mL | 31.3156 mL | |
| 5 mM | 0.6263 mL | 3.1316 mL | 6.2631 mL | |
| 10 mM | 0.3132 mL | 1.5658 mL | 3.1316 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04161768 | Recruiting | Drug: Norfloxacin Drug: Itopride |
Spontaneous Bacterial Peritonitis |
Tanta University | December 1, 2018 | Phase 3 |
| NCT05667818 | Not yet recruiting | Drug: Amlodipine besylate tablets (trade name: Norfloxacin ® sitafloxacin Drug: Amlodipine besylate controlled-release tablets |
Hypertension | Overseas Pharmaceuticals, Ltd. | January 28, 2023 | Phase 1 |
| NCT00362752 | Completed | Drug: Norfloxacin Drug: Placebo |
Hepatopulmonary Syndrome | Unity Health Toronto | October 2006 | Phase 2 |
| NCT00359853 | Completed | Drug: Oral norfloxacin | Hepatorenal Syndrome Cirrhosis |
Hospital Clinic of Barcelona | September 2000 | Phase 4 |
| NCT01542801 | Completed | Drug: Norfloxacin Drug:Drug: ciprofloxacin |
Adverse Reaction to Other Drugs and Medicines |
Korea University | August 2011 | Phase 4 |
|
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
